Abraxis Bioscience, LLC – FDA 483, Oct 6, 2023
Abraxis Bioscience, LLC, a sterile drug manufacturer in Phoenix, AZ, was cited with six observations during an FDA inspection from September 25 to October 6, 2023. The inspection revealed significant deficiencies across quality systems, including inadequate data integrity controls, incomplete investigations into out-of-specification results, and failures in maintaining aseptic processing equipment. Additional concerns involved insufficient secondary verification of laboratory records and poor management of reserve sample evaluations.
ID · aa826ec4-8ed3-4488-80ea-38b12127d3a0
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.